

CORRIGENDUM

DOI: 10.3892/ol.2019.10856

Polydatin inhibits hepatocellular carcinoma via the AKT/STAT3-FOXO1 signaling pathway

JIAN JIANG, YAODONG CHEN, TIANXIU DONG, MINLU YUE, YU ZHANG, TINGTING AN, JIUWEI ZHANG, PENGFEI LIU and XIUHUA YANG

Oncol Lett 17: 4505-4513, 2019; DOI: 10.3892/ol.2019.10123

Subsequently to the publication of this article, the authors have realized that Fig. 3 contained a duplicated panel: In Fig. 3A, the data correctly shown for the 0 h, 'Control' panel was inadvertently copied across to the 0 h, '100 $\mu\text{mol/l}$ ' panel. The revised version of Fig. 3, featuring the correct data for the 0 h, '100 $\mu\text{mol/l}$ ' panel, is shown opposite.

Note that this error did not affect the overall conclusions reported in the paper. The authors apologize to the Editor of *Oncology Letters* and to readership for any inconvenience caused.



This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.




Figure 3. Polydatin inhibits migration of HCCLM3 cells. (A) Suppressive effects of polydatin on migration were assessed via wound healing assay (magnification, $\times 200$). (B) Statistical analysis of the relative distances of cell migration. (C) Migration assay of HCCLM3 cells following treatment with polydatin at non-cytotoxic concentrations (0-150 $\mu\text{mol/l}$) (magnification, $\times 200$). (D) Statistical analysis of the number of cells crossing the membrane. *** $P < 0.001$ vs. control.